Creative Medical Technology (CELZ) Projected to Post Quarterly Earnings on Friday

Creative Medical Technology (NASDAQ:CELZ) is anticipated to announce its results after the market closes on Friday, May 8th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $0.0030 million for the quarter.

Creative Medical Technology (NASDAQ:CELZ) last posted its quarterly earnings results on Friday, March 20th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.43). The firm had revenue of $0.00 million during the quarter. On average, analysts expect Creative Medical Technology to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Creative Medical Technology Price Performance

Shares of Creative Medical Technology stock opened at $2.23 on Thursday. The business has a fifty day simple moving average of $2.04 and a 200 day simple moving average of $2.33. The stock has a market cap of $8.25 million, a PE ratio of -0.86 and a beta of 1.87. Creative Medical Technology has a 12 month low of $1.50 and a 12 month high of $6.25.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC acquired a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 1.17% of Creative Medical Technology as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.